Bulkamid is a minimally invasive injection procedure used to treat stress urinary incontinence (SUI) in women. A soft hydrogel is injected into the tissue surrounding the urethra to help it close more effectively, reducing urine leaks during activities like coughing, sneezing, or exercising. The FDA approved Bulkamid in January 2020, and the American Urological Association lists it as a viable surgical treatment option for SUI.
What Bulkamid Is Made Of
The gel itself is remarkably simple: 97.5% water and 2.5% cross-linked polyacrylamide. This composition makes it a soft, stable hydrogel that integrates into the surrounding tissue rather than breaking down or migrating over time. It comes pre-loaded in small 1 mL syringes, ready for injection.
How the Procedure Works
Stress urinary incontinence happens when the walls of the urethra don’t seal tightly enough to hold urine in during moments of physical pressure on the bladder. The urethra relies on its inner lining pressing together, called “coaptation,” to stay closed. In women with SUI, this seal is weakened.
During the Bulkamid procedure, a clinician uses a small camera (cystoscope) to see inside the urethra and injects the hydrogel into the tissue just beneath the urethral lining. The standard approach places injections at three points around the urethra, roughly at the 2, 6, and 10 o’clock positions, with 0.2 to 0.8 mL of gel at each site. These small cushions of gel bulk up the urethral wall, pushing the lining inward so it seals more completely. The result is greater resistance to urine escaping when you laugh, lift something heavy, or sneeze.
The injections are placed about 0.5 to 1 cm below the bladder neck, a very precise location that the clinician confirms visually through the camera in real time. The entire procedure is typically done in an outpatient setting and takes roughly 10 to 15 minutes.
What to Expect During and After
Bulkamid is usually performed under local anesthesia, sometimes with light sedation. You’re awake or lightly sedated, and most women go home the same day. There’s no surgical incision involved.
Recovery is quick compared to traditional surgery. The most common side effect in clinical trials was pain at the injection site, reported by about 12% of patients in a 228-person FDA study. Temporary difficulty urinating (acute urinary retention) occurred in about 6% of patients, but this resolved on its own. Notably, no patients in the trial experienced urinary retention lasting longer than seven days. Urinary tract infections occurred in about 3.5% of patients in the FDA trial, though broader reviews of bulking agents as a category put the UTI rate somewhat higher, around 7.5% on average across studies. Most women return to normal activities within a day or two.
How Well It Works
Bulkamid reduces leakage for many women, but it’s important to set realistic expectations. It tends to improve symptoms rather than eliminate them entirely, and its results are less durable than those of surgical slings. Data comparing the two approaches in older women on Medicare found a clear difference in retreatment rates: about 20% of women who received urethral bulking needed a repeat procedure within the first year, compared to 3.9% of those who had a midurethral sling. By five years, 24.6% of bulking patients had been retreated versus 6.7% of sling patients.
Looking at all repeat procedures (both retreatments and operations for complications), the five-year rates were 36.1% for bulking and 10.3% for slings. Urethral bulking carried roughly 3.9 times the risk of needing a second procedure compared to a sling.
That said, the tradeoff goes both ways. Among sling patients, 3.4% needed reoperation for complications within five years, compared to just 1.5% of bulking patients. Bulkamid is less likely to cause the kind of serious complications associated with mesh slings, like erosion or chronic pain. For women who want to avoid mesh or who have health conditions that make longer surgeries riskier, the lower complication profile can outweigh the higher chance of needing a top-up injection down the road.
Who It’s Best Suited For
The American Urological Association includes bulking agents as one of several options clinicians should discuss with women considering surgery for SUI. It’s listed alongside midurethral slings and other procedures as a Grade A recommendation, meaning there’s strong evidence supporting its use.
Bulkamid is particularly relevant for women with a fixed, immobile urethra, a condition where the urethra doesn’t move much during straining. In these cases, AUA guidelines suggest bulking agents as one of the appropriate treatment choices alongside certain sling procedures. It’s also commonly offered to women who prefer to avoid mesh implants, those who have already had a sling that didn’t fully resolve their symptoms, or older women for whom a shorter, less invasive procedure is medically preferable.
One of Bulkamid’s practical advantages is repeatability. If the initial injection doesn’t provide enough improvement, additional injections can be given in a follow-up visit using the same straightforward technique. This “start low and add more” approach gives both you and your clinician flexibility to adjust the treatment over time without committing to a more invasive surgery upfront.
How Bulkamid Compares to Other Options
Midurethral slings remain the most effective long-term surgical option for stress incontinence, with significantly lower retreatment rates over five years. They involve placing a small strip of synthetic mesh under the urethra to provide permanent support. For women without specific risk factors for mesh complications, slings typically deliver more durable results.
Bulkamid fills a different niche. It’s the least invasive surgical option, carries fewer serious complications, requires no general anesthesia in most cases, and allows a faster return to daily life. It works best as a first step for women who want meaningful improvement without the commitment and risks of a full surgical procedure, or as a secondary option when other treatments haven’t worked well enough. The key tradeoff is durability: you’re more likely to need additional treatments over time, but each individual treatment is quick, low-risk, and done in an office or outpatient setting.